Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
BJOG : an International Journal of Obstetrics and Gynaecology
|
July 31, 2015
A postpartum haemorrhage package with condom uterine balloon tamponade: a prospective multi-centre case series in Kenya, Sierra Leone, Senegal, and Nepal
T F Burke, R Ahn, B D Nelson, et al.
Transplantation Proceedings
|
November 18, 2009
Influence of human allogenic bone marrow and cord blood-derived mesenchymal stem cell secreting trophic factors on ATP (adenosine-5'-triphosphate)/ADP (adenosine-5'-diphosphate) ratio and insulin secretory function of isolated human islets from cadaveric donor
K S Park, Y S Kim, J H Kim, et al.
JCO Precision Oncology
|
June 12, 2024
Talazoparib in Patients With Solid Tumors With <i>BRCA1</i>/<i>2</i> Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study
Gordan Srkalovic, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
Apar K Ganti, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
April 7, 2023
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study
Eugene R Ahn, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Kelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Carmen J Calfa, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
BJOG : an International Journal of Obstetrics and Gynaecology
|
July 31, 2015
A postpartum haemorrhage package with condom uterine balloon tamponade: a prospective multi-centre case series in Kenya, Sierra Leone, Senegal, and Nepal
T F Burke, R Ahn, B D Nelson, et al.
Transplantation Proceedings
|
November 18, 2009
Influence of human allogenic bone marrow and cord blood-derived mesenchymal stem cell secreting trophic factors on ATP (adenosine-5'-triphosphate)/ADP (adenosine-5'-diphosphate) ratio and insulin secretory function of isolated human islets from cadaveric donor
K S Park, Y S Kim, J H Kim, et al.
JCO Precision Oncology
|
June 12, 2024
Talazoparib in Patients With Solid Tumors With <i>BRCA1</i>/<i>2</i> Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study
Gordan Srkalovic, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
Apar K Ganti, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
April 7, 2023
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study
Eugene R Ahn, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Kelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Carmen J Calfa, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Page
of 9